Clinical trial confirms GP-prescribed treatments are effective for women with heavy periods

Menstruation 2

PA 238/16 

The largest and longest running clinical trial of medical therapies for heavy periods has found that women can be greatly helped by having treatments just from their GP, with most avoiding hospital operations.

Heavy menstrual bleeding is a common and debilitating condition which can significantly affect the quality of life of 25 per cent of women aged 18-54. Around one million women seek help for this problem every year in the UK and it accounts for 12 per cent of all gynaecology referrals.

The multicentre NIHR-funded randomised controlled trial was carried out by researchers at the Universities of Nottingham and Birmingham and Aston University. They followed the cases of 571 women from 63 general practices across the Midlands over a five-year period. The results are published in the British Journal of General Practice.

12 Oct 2016 14:28:52.090
Click here for full story

The largest and longest running clinical trial of medical therapies for heavy periods has found that women can be greatly helped by having treatments just from their GP, with most avoiding hospital operations.

Heavy menstrual bleeding is a common and debilitating condition which can significantly affect the quality of life of 25 per cent of women aged 18-54. Around one million women seek help for this problem every year in the UK and it accounts for 12 per cent of all gynaecology referrals.

The multicentre NIHR-funded randomised controlled trial was carried out by researchers at the Universities of Nottingham and Birmingham and Aston University. They followed the cases of 571 women from 63 general practices across the Midlands over a five-year period. The results are published in the British Journal of General Practice.

The women who volunteered were randomly allocated to receive either a levonorgestrel Intra Uterine System such as the Mirena coil or commonly used oral medications — such as tranexamic/mefenamic acid or the contraceptive pill.

The patients were asked to report their menstrual experiences using the Menorrhagia Multi-Attribute Scale. This measures the effect of heavy periods on practical problems, social life, psychological and physical health as well as on work and family life. Other consequences recorded were surgical intervention, general quality of life, sexual activity and safety. 

After five years, both groups had similar and very significant improvement in the heaviness of their periods and its impact on their lives. Rates of surgical intervention were also low (80 per cent and 77 per cent did not have any surgery such as endometrial ablation or hysterectomy) with no significant difference between the coil group and those who took oral medications.

Leading the trial, GP and Professor of Primary Care, Joe Kai, said: “This is very encouraging news. Women were badly affected by heavy menstrual bleeding when they entered this trial, with most having problems for over a year beforehand. We know some women may be reluctant to seek help or be unaware that treatment is useful. Others may be put off by the idea of some treatments, such as having a coil, or of needing surgery. This trial shows women can be helped very considerably by treatments from their GP alone, with most avoiding hospital procedures up to five years later. It also shows women starting with either a Mirena coil or other oral medications will have similar benefit over time. This is helpful for women and their GPs to know when first considering what treatments to use, taking account of individual preferences and circumstances. If women troubled by heavy menstrual bleeding do choose to see their GP, we can be confident we can help.”

The researchers are following up the same women for a further five years — as by then around half will have reached the menopause — to assess if they are still using treatments or have needed surgical treatment for this problem.

The full research paper can be viewed online on the British Journal of General practice website.

— Ends —

Our academics can now be interviewed for broadcast via our Media Hub, which offers a Globelynx fixed camera and ISDN line facilities at University Park campus. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email mediahub@nottingham.ac.uk or see the Globelynx website for how to register for this service.

For up to the minute media alerts, follow us on Twitter

Notes to editors: The University of Nottingham has 43,000 students and is ‘the nearest Britain has to a truly global university, with a “distinct” approach to internationalisation, which rests on those full-scale campuses in China and Malaysia, as well as a large presence in its home city.’ (Times Good University Guide 2016). It is also one of the most popular universities in the UK among graduate employers and was named University of the Year for Graduate Employment in the 2017 The Times and The Sunday Times Good University Guide. It is ranked in the world’s top 75 by the QS World University Rankings 2015/16, and 8th in the UK for research power according to the Research Excellence Framework 2014. It has been voted the world’s greenest campus for four years running, according to Greenmetrics Ranking of World Universities.

Impact: The Nottingham Campaign, its biggest-ever fundraising campaign, is delivering the University’s vision to change lives, tackle global issues and shape the future. More news…

Story credits

More information is available from Professor Joe Kai in the School of Medicine, University of Nottingham, at joe.kai@nottingham.ac.uk; or Emma Rayner, Media Relations Manager for the Faculty of Medicine and Health Sciences at The University of Nottingham, on +44 (0)115 951 5793, emma.rayner@nottingham.ac.uk


Media Relations - External Relations

The University of Nottingham
YANG Fujia Building
Jubilee Campus
Wollaton Road
Nottingham, NG8 1BB

telephone: +44 (0) 115 951 5798
email: pressoffice@nottingham.ac.uk